

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.
艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

**CHANGE OF JOINT COMPANY SECRETARY,
AUTHORISED REPRESENTATIVE AND PROCESS AGENT**

The board (the “**Board**”) of directors (the “**Directors**”) of AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) hereby announces that Ms. Lam Wing Chi (“**Ms. Lam**”) has tendered her resignation as (i) a joint company secretary (the “**Joint Company Secretary**”); (ii) an authorised representative (the “**Authorised Representative**”) as required under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”); and (iii) the person authorised to accept service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”) due to adjustment of work arrangement, with effect from June 13, 2025.

The Board further announces that, following the resignation of Ms. Lam, Ms. Wong Pui Kiu Ingrid (黃沛翹) (“**Ms. Wong**”) has been appointed as the Joint Company Secretary, the Authorised Representative and the Process Agent of the Company with effect from June 13, 2025.

Ms. Lam has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the Stock Exchange and/or the shareholders of the Company.

After the aforesaid changes, Ms. Liu Ling (劉靈) (“**Ms. Liu**”) will continue to serve as the other Joint Company Secretary.

The biographical details of Ms. Liu are set out as follows:

Ms. Ling LIU (劉靈), has served in various management positions since she joined the Company in November 2011 and currently serves as Vice President, Board Secretary, and Chief Investment Officer. She is in charge of the general office of the Board and investment management of the Company. Her main responsibilities include such matters as information disclosure, investor relations, equity management and corporate governance of the Company. She has been appointed as a director of Liverna Therapeutics Inc. (珠海麗凡達生物技術有限公司) since May 2021.

Ms. Liu was the chairwoman of the board of AIM Rongyu (Ningbo) Biopharmaceutical Co., Ltd. (艾美榮譽(寧波)生物製藥有限公司) from December 2019 to June 2021. From February 2014 to January 2019, she was a director of AIM Persistence Biopharmaceutical Co., Ltd. (艾美堅持生物製藥有限公司). From August 2007 to May 2011, Ms. Liu served as the manager of the research and development department and vice president at Tibet Bohai Investment Holding Co., Ltd. (西藏渤海投資集團有限公司), a company primarily engaged in industrial investment and investment management.

Ms. Liu received her executive master of business administration degree from W.P. Carey in May 2018.

The biographical details of Ms. Wong are set out as follows:

Ms. Wong is currently a senior manager of Corporate Services of Tricor Services Limited, a global professional services provider specializing in integrated Business, Corporate and Investor Services. Ms. Wong has over 10 years' experience in the corporate secretarial and legal advisory services. Ms. Wong holds a Master of Science degree in Corporate Governance and Compliance from the Hong Kong Baptist University, a Bachelor of Laws degree from The University of Law in London, the United Kingdom, and a Bachelor of Business Administration degree in Global Business and Management of Organizations from The Hong Kong University of Science and Technology. Ms. Wong is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute (HKCGI) and The Chartered Governance Institute (CGI) in the United Kingdom.

Ms. Wong meets the qualification requirements for a company secretary under Rules 3.28 and 8.17 of the Listing Rules.

The Board wishes to take this opportunity to express its gratitude to Ms. Lam for her contribution during her tenure of offices and express its welcome to Ms. Wong on her appointment.

Waiver from Strict Compliance with Rules 3.28 and 8.17 of the Listing Rules

Reference is made to the appointment of Ms. Lam as one of the Joint Company Secretaries and the waiver granted to the Company by the Stock Exchange from strict compliance with Rules 3.28 and 8.17 of the Listing Rules (the “**Waiver**”) in relation to the eligibility of Ms. Liu to act as the Joint Company Secretary for a period of three years from the date of listing of the Company (i.e. October 6, 2022) to October 5, 2025 (the “**Waiver Period**”) on the conditions that (i) Ms. Liu will be assisted by Ms. Lam during the Waiver Period; and (ii) the Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

In view of Ms. Lam’s resignation and since Ms. Lim does not possess the qualifications of company secretary as required under Rule 3.28 of the Listing Rules, the Company has applied for, and the Stock Exchange has granted, a new waiver from strict compliance with Rules 3.28 and 8.17 of the Listing Rules (the “**New Waiver**”) for a period from the date of said appointment of Ms. Wong to October 5, 2025 (the “**Remaining Waiver Period**”) on the conditions that Ms. Liu will be assisted by Ms. Wong during the Remaining Waiver Period and the New Waiver will be revoked if there are material breaches of the Listing Rules by the Company. Ms. Wong, as a Joint Company Secretary who meets the requirements under Rule 3.28 of the Listing Rules, will work closely with, and provide assistance to, Ms. Liu in discharging her duties as a Joint Company Secretary and in gaining the relevant experience as required under Rule 3.28 of the Listing Rules.

The Company shall notify the Stock Exchange before the expiry of the Remaining Waiver Period for the Stock Exchange to re-visit the situation. The Stock Exchange expects that before the expiry of the New Waiver Period, the Company must demonstrate and seek the Stock Exchange’s confirmation that Ms. Liu, having had the benefit of Ms. Wong’s assistance during the Remaining Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary and the Company will disclose details of the New Waiver, including the reasons for, details and the conditions of the New Waiver, by way of announcement.

By order of the Board
AIM Vaccine Co., Ltd.

Chairman of the Board and CEO Mr. Yan ZHOU

Beijing, the PRC, June 13, 2025

As at the date of this announcement, the Board comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Shaojun JIA, Mr. Wen GUAN and Mr. Jie ZHOU as executive directors; Mr. Jichen ZHAO as non-executive director; and Professor Ker Wei PEI, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive directors.